Please login to the form below

Immunotherapies in oncology: the future of cancer treatment lies in combinations and partnerships

Anne Legendre reviews the scientific rationale behind immunotherapy combinations and Frances Hendry examines how partnerships, co-marketing and positioning drugs will play key roles in shaping the competitive landscape in oncology.
With the promise of using the body’s own immune system to fight cancer, immunotherapy has received significant interest from the scientific community, bringing hope to patients across many cancer indications.

The recent development of immunotherapies has led to considerable change in the oncology treatment landscape, driving transformation in the standard of care and yielding lasting responses in patients with metastatic cancers.
While promising, first and second generations of agents have demonstrable weaknesses too, such as:
  • Reduced efficacy in a limited subset of patients
  • Increased resistance mechanism, where patients do not respond or stop responding
  • Toxicity issues, which diminish quality of life for patients.
In order to optimise agent efficacy and overall patient survival, most of these agents are now used in combination. This shift has led to a proliferation of combination studies and approvals, as well as research and commercial partnerships between top pharma companies and small biotechnology companies with innovative product pipelines.

What are the immunotherapy agents currently investigated in monotherapy and in combination?

The first generation of agents has shown some interesting results, while also highlighting the limits of immunotherapies in oncology.

Yervoy (ipilimumab, Bristol-Myers Squibb) is a first-generation agent which was approved by the FDA in 2011 for advanced melanoma.

The second wave of agents encompasses checkpoint inhibitors and cell therapies, among others. Nivolumab, pembrolizumab and atezolizumab are checkpoint inhibitors, meaning that they help the immune system to recognise and kill tumour cells. These three agents have been approved in the US and Europe for multiple indications, where they have shown promising efficacy.

Third-generation agents are emerging. These are a broader set, targeting other aspects of the immune system. They promise multiple therapeutic options that can be tailored to the patient and offer a wide range of possibilities for combination (Hoos et al, 2016).
 

Download the full article from Blue Latitude Health

7th July 2017

Share

Tags

Company Details

Blue Latitude Health

+44 203 328 1840

Contact Website

Address:
Blue Latitude Health (UK)
140 Aldersgate Street
London
EC1A 4HY
United Kingdom

Latest content on this profile

Diagnosing the lag in neuropsychiatric treatments
The number of mental health research programmes in larger drug firms has shrunk by 70% in the past decade. Blue Latitude Health Senior Associate Consultant Sana Rahim explores this drop in investment and explains why developing a market-orientated model is vital for making progress.
Blue Latitude Health
Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking CAR-T therapy for the first patient in Europe, and how the centre of excellence has adapted to make precision medicine a reality
Blue Latitude Health
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market.
Blue Latitude Health
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives his side of the story and explains how industry can help oncologists treat more patients with targeted therapies.
Blue Latitude Health
Battling breast cancer with precision medicine (Part 1)
Laura Holmes Haddad is a breast cancer survivor. She made the incredibly brave decision to participate in a PARP inhibitor precision medicine trial. Here, the author and precision medicine advocate tells her story and explains what industry needs to remember when treating cancer patients with precision medicine.
Blue Latitude Health
The role of brain health in treating MS
Blue Latitude Health speaks to Professor Gavin Giovannoni, key opinion leader and Chair of Neurology, Barts and The London School of Medicine and Dentistry, about his theories on brain health, the importance of a holistic approach to MS and why digital technology is the future of effective MS care.
Blue Latitude Health